摘要: 肝硬化是一种由各种慢性肝损伤导致的进展性疾病,随着肝脏免疫微环境和血流动力学的改变,肠肝轴功能的紊乱在肝硬化的发生和发展中起到关键作用。本文详细阐述肠肝轴在肝硬化疾病发生和发展中的详细作用过程,包括肠道屏障损伤、菌群代谢紊乱及全身炎症级联反应失控;并重点评述针对肠肝轴功能损伤机制的不同治疗方式,包括调节菌群稳态、重建肠道菌群微生态、修复肠道屏障、阻断毒性代谢物等。尽管目前临床前研究结果积极,但仍缺乏个体化治疗的标准与经验,且需要长期的安全性验证,期望未来研究能够通过探索肠肝轴在微生物学和合成生物学技术方面的应用,实现多靶点精准辅助治疗肝硬化。
薛俊杰, 陈楠, 陈萌萌, 奉镭. 肠肝轴在肝硬化中的作用机制及靶向治疗新策略[J]. 肝脏, 2026, 31(9): 1371-1375.
| [1] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis[J]. Lancet, 2021,398(10308):1359-1376. [2] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020,396(10258):1204-1222. [3] Liu Y B, Chen M K. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions[J]. World J Gastroenterol, 2022,28(41):5910-5930. [4] Yi Q, Yang J, Wu Y, et al. Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells[J]. Front Immunol, 2023,14:1204524. [5] Danielsen K V, Wiese S, Busk T, et al. Cardiovascular mapping in cirrhosis from the compensated stage to hepatorenal syndrome: a magnetic resonance study[J]. Am J Gastroenterol, 2022,117(8):1269-1278. [6] Simbrunner B, Mandorfer M, Trauner M, et al. Gut-liver axis signaling in portal hypertension[J]. World J Gastroenterol, 2019,25(39):5897-5917. [7] Tilg H, Adolph T E, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab, 2022,34(11):1700-1718. [8] Anand S, Mande S S. Host-microbiome interactions: gut-liver axis and its connection with other organs[J]. NPJ Biofilms Microbiomes, 2022,8(1):89. [9] Fukui H. Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update[J]. Gut Liver, 2021,15(5):666-676. [10] Odenwald M A, Turner J R. The intestinal epithelial barrier: a therapeutic target?[J]. Nat Rev Gastroenterol Hepatol, 2017,14(1):9-21. [11] Pellegrini C, Fornai M, D'Antongiovanni V, et al. The intestinal barrier in disorders of the central nervous system[J]. Lancet Gastroenterol Hepatol, 2023,8(1):66-80. [12] Ding C, Wang Z, Dou X, et al. Farnesoid X receptor: from structure to function and its pharmacology in liver fibrosis[J]. Aging Dis, 2024,15(4):1508-1536. [13] Xu X, Lu F, Yu D, et al. Cortex Dictamni induces cholestatic liver injury via the bile acid-gut-liver axis mediated by FXR signaling pathway in rats[J]. J Ethnopharmacol, 2025,351:120019. [14] Simbrunner B, Hofer B S, Schwabl P, et al. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence[J]. Hepatol Int, 2024,18(3):929-942. [15] Leshem A, Liwinski T, Elinav E. Immune-microbiota interplay and colonization resistance in infection[J]. Mol Cell, 2020,78(4):597-613. [16] Barbaro M R, Cremon C, Morselli-Labate A M, et al. Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity[J]. Gut, 2020,69(11):1966-1974. [17] Luo X, Wang K, Jiang C. Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects[J]. Cell Host Microbe, 2025,33(6):836-853. [18] Violi F, Nocella C, Bartimoccia S, et al. Gut dysbiosis-derived low-grade endotoxemia: a common basis for liver and cardiovascular disease[J]. Kardiol Pol, 2023,81(6):563-571. [19] Xirouchakis E, Pelekanos A, Xirouchakis S, et al. A systematic review of microbiota in cirrhosis: a change towards a more pathogenic predisposition[J]. Int J Mol Sci, 2025,26(2):527. [20] Qin X, Chen M, He B, et al. Role of short-chain fatty acids in non-alcoholic fatty liver disease and potential therapeutic targets[J]. Front Microbiol, 2025,16:1539972. [21] Gao Y, Yao Q, Meng L, et al. Double-side role of short chain fatty acids on host health via the gut-organ axes[J]. Anim Nutr, 2024,18:322-339. [22] Shang H, Huang C, Xiao Z, et al. Gut microbiota-derived tryptophan metabolites alleviate liver injury via AhR/Nrf2 activation in pyrrolizidine alkaloids-induced sinusoidal obstruction syndrome[J]. Cell Biosci, 2023,13(1):127. [23] Andreu-Sánchez S, Ahmad S, Kurilshikov A, et al. Unraveling interindividual variation of trimethylamine N-oxide and its precursors at the population level[J]. iMeta, 2024,3(3):e183. [24] Wang M, Li XS, Wang Z, et al. Trimethylamine N-oxide is associated with long-term mortality risk: the multi-ethnic study of atherosclerosis[J]. Eur Heart J, 2023,44(18):1608-1618. [25] Zhang H, Tang M, Liu Q, et al. PAT exposure caused human hepatocytes apoptosis and induced mice subacute liver injury by activating oxidative stress and the ERS-associated PERK pathway[J]. Sci Total Environ, 2024,955:177003. [26] Guan H, Zhang X, Kuang M, et al. The gut-liver axis in immune remodeling of hepatic cirrhosis[J]. Front Immunol, 2022,13:946628. [27] Andrikopoulos P, Aron-Wisnewsky J, Chakaroun R, et al. Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide[J]. Nat Commun, 2023,14(1):5843. [28] McGettigan B, Hernandez-Tejero M, Malhi H, et al. Immune dysfunction and infection risk in advanced liver disease[J]. Gastroenterology, 2025,168(6):1085-1100. [29] Sobolev V, Tchepourina E, Soboleva A, et al. PPAR-γ in melanoma and immune cells: insights into disease pathogenesis and therapeutic implications[J]. Cells, 2025,14(7):534. [30] Yang Y, Yang L, Wu J, et al. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: a systematic review and network meta-analysis[J]. Clin Nutr, 2024,43(6):1224-1239. [31] Lee S Y, Lee S B, Kwon G H, et al. Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease[J]. J Microbiol, 2025,63(2):e2411002. [32] Huang L, Yu Q, Peng H, et al. Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2022,101(51):e32335. [33] Saeed H, Díaz L A, Gil-Gómez A, et al. Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease[J]. Clin Mol Hepatol, 2025,31(Suppl):S94-S111. [34] Zhang C, Zhang Q, Zhang X, et al. Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial[J]. Clin Nutr, 2025,44:248-258. [35] Mantri A, Köhlmoos A, Schelski D S, et al. Impact of synbiotic intake on liver metabolism in metabolically healthy participants and its potential preventive effect on metabolic-dysfunction-associated fatty liver disease (MAFLD): a randomized, placebo-controlled, double-blinded clinical trial[J]. Nutrients, 2024,16(9):1300. [36] Vallianou N, Stratigou T, Christodoulatos G S, et al. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives[J]. Curr Obes Rep, 2020,9(3):179-192. [37] Yuan Q, Fang Y, Guo J, et al. Therapeutic potential and mechanisms of rifaximin in ameliorating iron overload-induced ferroptosis and liver fibrosis in vivo and in vitro[J]. Toxicol Appl Pharmacol, 2024,484:116845. [38] Sanyal A J, Kowdley K V, Reau N S, et al. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence[J]. Hepatol Commun, 2024,8(6):e0436. [39] Yang W, Guo G, Sun C. Therapeutic potential of rifaximin in liver diseases[J]. Biomed Pharmacother, 2024,178:117283. [40] Idalsoaga F, Robles C, Ortiz A, et al. Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy[J]. Therap Adv Gastroenterol, 2024,17:17562848241254267. [41] Teklemariam A D, Al Hindi R, Qadri I, et al. Phage cocktails-an emerging approach for the control of bacterial infection with major emphasis on foodborne pathogens[J]. Biotechnol Genet Eng Rev, 2024,40(1):36-64. [42] Gan L, Feng Y, Du B, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae[J]. Nat Commun, 2023,14(1):3215. [43] Shah Y R, Ali H, Tiwari A, et al. Role of fecal microbiota transplant in management of hepatic encephalopathy: current trends and future directions[J]. World J Hepatol, 2024,16(1):17-32. [44] Saha S, Schnabl B. Modulating the microbiome in chronic liver diseases-current evidence on the role of fecal microbiota transplantation[J]. Expert Rev Gastroenterol Hepatol, 2025,19(1):53-64. [45] Zeng J, Zhao D, Way G, et al. Intestinal mucosal mitochondrial oxidative phosphorylation worsens with cirrhosis progression and is ameliorated with fecal microbiota transplantation[J]. JCI Insight, 2025,10(4):e186649. [46] Abenavoli L, Maurizi V, Rinninella E, et al. Fecal microbiota transplantation in NAFLD treatment[J]. Medicina (Kaunas), 2022,58(11):1559. [47] Tun K M, Hong A S, Batra K, et al. A systematic review of the efficacy and safety of fecal microbiota transplantation in the treatment of hepatic encephalopathy and clostridioides difficile infection in patients with cirrhosis[J]. Cureus, 2022,14(5):e25537. [48] Sanyal A J, Lopez P, Lawitz E J, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial[J]. Nat Med, 2023,29(2):392-400. [49] Ratziu V, Harrison S A, Loustaud-Ratti V, et al. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH[J]. J Hepatol, 2023,78(3):479-492. [50] Hu D Y, Wu M Y, Chen G Q, et al. Metabolomics analysis of human plasma reveals decreased production of trimethylamine N-oxide retards the progression of chronic kidney disease[J]. Br J Pharmacol, 2022,179(17):4344-4359. [51] Wu W K, Lo Y L, Chiu J Y, et al. Gut microbes with the gbu genes determine TMAO production from L-carnitine intake and serve as a biomarker for precision nutrition[J]. Gut Microbes, 2025,17(1):2446374. [52] Zhou D, Zhang J, Xiao C, et al. Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis[J]. Front Immunol. 2022,13:964477. [53] Emidio N B, Meli R, Tran H N T, et al. Chemical synthesis of TFF3 reveals novel mechanistic insights and a gut-stable metabolite[J]. J Med Chem, 2021,64(13):9484-9495. [54] Hendrikx T, Duan Y, Wang Y, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice[J]. Gut, 2019,68(8):1504-1515. [55] Pasta A, Formisano E, Calabrese F, et al. From dysbiosis to hepatic inflammation: a narrative review on the diet-microbiota-liver axis in steatotic liver disease[J]. Microorganisms, 2025,13(2):241. [56] 中国研究型医院学会肝病(中西医结合)专业委员会病毒性肝炎学组,浙江省慢性肝病重症化精准诊治与规模转化重点实验室,陈永平. 肝硬化患者粪菌移植治疗指南[J]. 临床肝胆病杂志,2025,41(3):424-431. [57] Hamilton J R, Chen E, Perez B S, et al. In vivo human T cell engineering with enveloped delivery vehicles[J]. Nat Biotechnol, 2024,42(11):1684-1692. |
| [1] | 杨婉婷, 陈启鑫, 谢雯. 从失代偿到再代偿:《Baveno Ⅷ门静脉高压共识》的部分解读[J]. 肝脏, 2026, 31(9): 1218-1222. |
| [2] | 申文娟, 杨力, 罗亮. 淋巴细胞与单核细胞比值对危重症肝硬化预后的预测价值:基于MIMIC数据库[J]. 肝脏, 2026, 31(9): 1236-1242. |
| [3] | 赵凤丛, 依力哈木·阿不力提甫, 张永萍. 3 185例肝硬化住院患者病因及临床特征分析[J]. 肝脏, 2026, 31(9): 1243-1246. |
| [4] | 刘佩, 张顺玲, 曾雪丽, 李心怡, 郑盛, 杨涓. Rockall评分、Blatchford评分、AIMS65评分及联合应用对肝硬化患者短期内上消化道出血风险的预测价值[J]. 肝脏, 2026, 31(9): 1247-1252. |
| [5] | 顾征太, 刘炜炜, 顾凌云, 马陈斌. 构建预测肝硬化患者隐性肝性脑病首次发作风险的列线图[J]. 肝脏, 2026, 31(9): 1253-1257. |
| [6] | 赵妍妍, 李福祥, 刘璐璐. 外周血CCL5联合CXCL14对乙型肝炎肝硬化失代偿期并发肝衰竭患者生存结局的预测价值[J]. 肝脏, 2026, 31(9): 1267-1272. |
| [7] | 陈芳芳, 李静, 杨晓娟, 张文杰, 卡毛加, 周宁. 肠道微生态在代谢相关脂肪性肝病中的调控机制与精准干预研究进展[J]. 肝脏, 2026, 31(9): 1366-1371. |
| [8] | 唐静, 张亮, 王艳, 肖贵宝. 艾米替诺福韦治疗乙型肝炎肝硬化2例并文献复习[J]. 肝脏, 2026, 31(9): 1378-1380. |
| [9] | 许丹青, 木唤, 张映媛, 牟春燕, 撒采芬, 刘立, 李卫昆. 肝硬化急性失代偿患者的临床特征及预后[J]. 肝脏, 2026, 31(8): 1084-1090. |
| [10] | 吕敏, 刘雯, 谷梦迪, 姚智博, 丁芹. 乙型肝炎肝硬化患者食管胃底静脉破裂出血后获得再代偿的影响因素分析[J]. 肝脏, 2026, 31(8): 1091-1095. |
| [11] | 蒋花叶, 范咏梅. 肝硬化患者QTc间期延长的危险因素[J]. 肝脏, 2026, 31(8): 1101-1106. |
| [12] | 张炎, 魏汝峰, 张春玲, 杨琳, 肖琰. 超声造影特征对肝硬化增生结节与小肝癌的诊断价值[J]. 肝脏, 2026, 31(8): 1115-1119. |
| [13] | 魏莹莹, 周丰, 王晓今, 周荣. 垂体柄阻断综合征导致肝硬化1例并文献复习[J]. 肝脏, 2026, 31(8): 1199-1199. |
| [14] | 徐贝琪, 刘爱芳, 邹波, 张丹丹, 罗磊, 杨文龙. 2026年《关于PSVD或NCPF新通用定义及诊断标准的多学会共识声明》摘译[J]. 肝脏, 2026, 31(7): 945-947. |
| [15] | 许丹青, 撒采芬, 牟春燕, 李文彦, 木唤, 刘立, 张映媛. 失代偿期酒精性肝炎肝硬化患者再代偿的预测模型构建及效能评估[J]. 肝脏, 2026, 31(7): 948-953. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||